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ABSTRACT
The establishment of an abundant source of autologous cardiac progenitor cells would represent a
major advance toward eventual clinical translation of regenerative medicine strategies in children
with prenatally diagnosed congenital heart disease. In support of this concept, we sought to examine
whether functional, transgene-free human cardiomyocytes (CMs) with potential for patient-specific
and autologous applications could be reliably generated following routine amniocentesis. Under in-
stitutional review board approval, amniotic fluid specimens (8–10ml) at 20weeks gestationwere ex-
panded and reprogrammed toward pluripotency using nonintegrating Sendai virus (SeV) expressing
OCT4, SOX2, cMYC, and KLF4. Following exposure of these induced pluripotent stem cells to cardio-
genic differentiation conditions, spontaneously beating amniotic fluid-derived cardiomyocytes (AF-CMs)
were successfully generated with high efficiency. After 6 weeks, quantitative gene expression
revealed amixed population of differentiated atrial, ventricular, and nodal AF-CMs, as demonstrated
by upregulation of multiple cardiac markers, including MYH6, MYL7, TNNT2, TTN, and HCN4, which
were comparable to levels expressed by neonatal dermal fibroblast-derived CM controls. AF-CMs
had a normal karyotype and demonstrated loss of NANOG, OCT4, and the SeV transgene. Functional
characterization of SIRPA+ AF-CMs showed a higher spontaneous beat frequency in comparison with
dermal fibroblast controls but revealed normal calcium transients and appropriate chronotropic re-
sponses afterb-adrenergic agonist stimulation. Taken together, these data suggest that somatic cells
present within human amniotic fluid can be used to generate a highly scalable source of functional,
transgene-free, autologousCMsbeforea child isborn. This approachmaybe ideally suited forpatients
with prenatally diagnosed cardiac anomalies. STEMCELLS TRANSLATIONALMEDICINE 2016;5:1595–1606
SIGNIFICANCE
This study presents transgene-free human amniotic fluid-derived cardiomyocytes (AF-CMs) for po-
tential therapy in tissue engineering and regenerative medicine applications. Using 8–10 ml of am-
niotic fluid harvested at 20 weeks gestation from normal pregnancies, a mixed population of atrial,
ventricular, and nodal AF-CMswere reliably generated after Sendai virus reprogramming toward plu-
ripotency. Functional characterization of purified populations of beating AF-CMs revealed normal
calcium transients and appropriate chronotropic responses after b-adrenergic agonist stimulation
in comparison with dermal fibroblast controls. Because AF-CMs can be generated in fewer than
16weeks, this approachmay be ideally suited for eventual clinical translation at birth in childrenwith
prenatally diagnosed cardiac anomalies.
INTRODUCTION
Congenital heart defects (CHD) are the most com-
montypeofbirthdefect in theUnitedStates, affect-
ing nearly 1% of births per year [1]. Almost half
of these cases are now diagnosed prenatally by ul-
trasound [2]. Many of these children will ultimately
requiremajorheart surgeryorother invasiveproce-
dures as infants, and approximately 25%will die be-
fore 1 year of age under conventional medical and
surgical treatment [1, 3]. There remains a critical
need for new technologies to better understand
thepathogenesis of CHDand to developnovel ther-
apeutic approaches that can improve the lives of
these children and their families.
The reliable generation of patient-specific
cardiomyocytes (CMs) from induced pluripotent
stem cells (iPSCs) before a child is even born is
a relatively novel regenerative medicine strat-
egy thatmight bring newhope in CHD [4, 5]. Car-
diac anomalies are composed of a heterogeneous
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models exist [6]. Patient-specific CMs could therefore provide a use-
ful in vitromodel to studydisease pathogenesis.Moreover, the gen-
eration of autologous CMs using nonintegrating techniques
would provide new avenues for the development of cardiac
cell-based therapies and three-dimensional (3D) engineered
microtissues aimed at treating heart failure, either prenatally
or in the early postnatal period, as an alternative to cadaveric
heart transplantation.
In this study, wehypothesized that functional, transgene-free
CMs with potential for patient-specific and autologous perinatal
applications could be reliably generated in a minimally invasive
fashion from somatic cells normally obtained by routine amnio-
centesis. For the first time, we show the successful generation
of functional, transgene-free CMs derived from fetal amniotic
fluid iPSCs innormalpatients. TheseCMswere subsequently com-
pared with CMs derived from postnatal dermal fibroblasts. We
further demonstrate that human CMs generated from amniotic
fluid have similar phenotypic and functional properties in compar-
ison with fibroblast-derived controls and may therefore be ideally
suited for cardiac regenerative therapies in fetuses and neonates
with prenatally diagnosed cardiac anomalies.
MATERIALS AND METHODS
Human Specimens
Approval for this work was obtained from the University of Michigan
(IRB 38565 and HPSCRO 1044). After written informed consent,
human somatic cells were obtained from normal 20-week gesta-
tion unused amniocentesis samples (n = 2, 8–10 ml) performed
for obstetrical indications. Specimen donations were anony-
mous and would have otherwise been discarded as waste. As
controls, neonatal foreskin specimens (n = 2) were obtained
following elective circumcision. All patients were confirmed
to have normal heart function postnatally. After 24–48 hours,
nonadherent cells were removed by washing the plates with
phosphate-buffered saline, and the medium was replaced as
previously described [7].
Somatic Cell Characterization
Between passages 3 and 5, skin dermal fibroblasts and amniocytes
werephenotypically characterized forpluripotencyandmesenchy-
mal stem cell (MSC) features on the basis of criteria as described
elsewhere [8]. Differentiation intomesenchymal lineages was per-
formedatpassage4, asdetailedelsewhere [9]. For flowcytometry,
primary antibodies usedwere phycoerythron-conjugated against
CD34, CD44, CD45, CD73, CD90, CD105, CD117 (c-kit), OCT4A,
SOX2, SSEA3, SSEA4, TRA-1-60, TRA-1-81, and human leukocyte
antigen-antigen D related (HLA-DR) (all from BD Biosciences,
San Diego, CA, http://www.bdbiosciences.com). Cells were fixed
with 2% paraformaldehyde prior to evaluation of antibody stain-
ing using a LSRII flow cytometer (BD Biosciences). Resulting data
were analyzed using FloJo software (Tree Star, Ashland, OR, http://
www.flowjo.com).
iPSC Derivation
Integration-free iPSC derivation was performed using a noninte-
grating, cytoplasmic Sendai virus (SeV) encoding for OCT4, SOX2,
KLF4, and cMYC (OSKM)at 33106 cell infectious units (CytoTune-
iPS Reprogramming Kit, Thermo Fisher Scientific Life Sciences,
Waltham,MA, https://www.thermofisher.com), as previously
described in our laboratory [10]. Briefly, 2 3 105 amniotic fluid
mesenchymal stromal cells (AF-MSCs) or dermal fibroblasts were
exposed to SeV for 24 hours and subsequently placed on irra-
diated mouse embryonic fibroblast (MEFs) feeder layers. All
cells, including H1- and H9- human embryonic stem cell (ESC)
controls (WiCell, Madison, WI, http://www.wicell.org), were
cultured in human embryonic stem cell conditioned medium
(GlobalStem, Gaithersburg, MD, http://www.globalstem.com)
with 4 ng/ml of FGF-2 (Millipore, Damstadt, Germany, http://
www.emdmillipore.com). Individual colonies were subsequently
picked mechanically and propagated on MEFs or Matrigel (BD
Biosciences).
Alkaline phosphatase (AP) staining was performed using
the AP substrate kit (Millipore), according to the manufac-
turer’s instructions. Immunofluorescence staining was used
to assay pluripotency in established iPSC lines. Primary anti-
bodies against NANOG (Abcam, Cambridge, MA, http://www.
abcam.com), OCT4 (Santa Cruz Biotechnology, Dallas, TX,
http://www.scbt.com), SOX2, SSEA3, SSEA4, TRA-1-60, and
TRA-1-81 (Millipore) were used. Cells were examined using
epifluorescence microscopy (DM IRB, Leica, Buffalo Grove, IL,
http://www.leica-microsystem.com). Karyotyping was performed
on iPSCs by Cell Line Genetics (Madison, WI, http://www.
clgenetics.com).
Embryoid Body Assay
Embryoid bodies (EBs)were formed in suspension culture and an-
alyzed using methods previously described [11]. Primary anti-
bodies were against neuron-specific class b-III tubulin (TuJ1;
Covance, Battle Creek, MI, http://www.covance.com), SOX17
(R&D Systems, Minneapolis, MN, http://www.rndsystems.com),
and a-smooth muscle actin (SMA).
Cardiomyocyte Differentiation
iPSC clones (two per experiment) at passages 10 to 14 were incu-
bated with TrypleE (Invitrogen) at 37°C for 5 minutes to obtain a
single cell suspension. CMdifferentiation of iPSCswas performed
using one of two establishedmonolayer differentiation protocols
in our laboratory. In the first approach, we used modifications of
theMatrigel sandwich technique, as previously detailed [12]. We
seeded 30,000 cells onto silicone membranes within Matrigel-
coated12-well plates inmTESR1medium(StemCell Technologies,
Vancouver, British Columbia, Canada, http://www.stemcell.com)
and grew them to 80%–90% confluence, at which time the wells
were overlaid with 1 ml Matrigel per well. Once the cells were
100% confluent, themediumwas replacedwith Roswell ParkMe-
morial Institute (RPMI) 1640 (Invitrogen) containing B27 without
insulin (Invitrogen), 100 ng/ml activin A (R&D Systems), and
Matrigel. After 24 hours, the media were supplemented with
10 ng/ml BMP4 (R&D Systems) and 10 ng/ml FGF-2 (Millipore)
for another 4 days prior to changing to basal media containing
B27 with insulin (Invitrogen) for up to 90 days. In the small-
molecule cardiac induction protocol as described elsewhere
[13], the media on day 0 were replaced with RPMI 1640 contain-
ing B27 without insulin and 12 mM glycogen synthase kinase
3B inhibitor (CHIR99021, Selleck, Houston, TX, http://www.
selleckchem.com) for 24 hours to activate canonical Wnt sig-
naling. On day 3, the media were supplemented with 5mMpor-
cupine palmitylation inhibitor (IWP-4, Stemgent, Cambridge,
MA, http://www.stemgent.com) for 24 hours to inhibit Wnt
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signaling. The media were then changed to basal media contain-
ing B27 with insulin for up to 90 days.
Cardiomyocyte Separation
For all functional testing, enrichment for stem cell-derived CMs
was performed on the basis of positive expression of signal reg-
ulatory protein a (SIRPA, CD172a; Miltenyi Biotec, San Diego,
CA, http://www.miltenyibiotec.com) expression, as detailed
elsewhere [14]. Briefly, CMs between 30 and 40 days were dis-
sociated with 0.25% tryspin-EDTA at 37°C for 5 minutes and
neutralized in EB20 medium. Cells were then incubated with
antibiotin magnetic microbeads conjugated with SIRPA anti-
body at 4°C for 10 minutes and positively selected by passing
the cell suspension through magnetic columns on a magnetic
separator (Miltenyi Biotec). We seeded 300,000 cells onto sili-
cone membranes coated with Matrigel in EB20 medium in
12-well plates. The media were replaced after 48 hours with
RPMI1640plusB27 inpreparation for electrophysiologic testing
1 week later. Assessment of CM purification was performed by
flow cytometry using a cardiac troponin (cTnT) antibody (Miltenyi
Biotec).
Gene Expression Analysis
Total RNAwas extracted fromcells using TRIzol (Invitrogen). First-
strand cDNA was prepared with the Taqman Reverse Transcrip-
tion Reagent kit (Applied Biosystems, c). Reverse transcription
polymerase chain reaction (RT-PCR) was performed in triplicate
at 35 cycles. The primer sequences for RT-PCR can be found in
supplemental online Table 1.Quantitative PCR (qPCR)was carried
out on aMastercycler ep realplex (Eppendorf, Hamburg, Germany,
http://www.eppendorf.com) using Fast SYBR Green Master Mix
(Applied Biosystems), as recommended by the manufacturer. Rel-
ative gene expression of cardiac-specific myofilament and pluripo-
tency transcripts was analyzed by qPCR with GAPDH used as a
reference gene to normalize target gene expression using the
2-ΔΔCt method [15]. The primer sequences used for qPCR are
provided in supplemental online Table 2.
Microarray Analysis
To compare transcriptomes among the different cell types, we
performed a customized microarray analysis of 88 genes on
the basis of the Cardiovascular Disease PCR array kit (PAHS-
174Z, QIAGEN, Valencia, CA, http://www.sabiosciences.com).
A list of genes is shown in supplemental online Tables 3 and
4. Total RNAwas extracted using theMagMAX-96 Total RNA Iso-
lation Kit andMAGMax Express (Applied Biosystems) from ran-
domly selected parental, iPSC, and SIRPA+ CMs. RNA quality
and quantity were determined spectrophotometrically using
Nano Drop 2000 (Thermo Fisher, Waltham, MA, https://www.
thermofisher.com). Sample processing, probing to the Hu-
man Gene 2.1 ST array platform (Affymetrix, Santa Clara, CA,
http://www.affymetrix.com), and data analysis were per-
formed by the University of Michigan DNA Sequencing Core
Microarray Facility. Normalized expressions by robust multiple-
array averages were plotted using the heatmap.2 function from
the gplots package in R (http://www.r-project.org) using default
parameters. The Euclidean distance dissimilaritymatrix and com-
plete linkage method were used to generate dendrograms and
heatmap images. After exclusion of genes that were not present,
we normalized values (in relation to housekeeping genes) on the
basis of a 0-to-25 scale,with high expression shown in redand low
expression shown in yellow.
Immunocytochemistry
For immunofluorescence analysis of cell type restricted pro-
teins, cells were fixed in 4% paraformaldehyde and stained
with primary antibodies against a-actinin (Sigma-Aldrich, St.
Louis, MO, www.sigma-aldrich.com), myosin heavy chains
(MF20 and MYH7), MLC2v (Proteintech, Chicago, IL, http://
www.ptglab.com), or connexin-43 (CX43). Cells were counter-
stained with 4’,6-diamidino-2-phenylindole (DAPI). Confocal
imaging was performed by using a Zeiss LSM 510 and Nikon
A-1 confocal system. Cell size was measured using the NIS-
Elements (Nikon, Tokyo, Japan, www.nikonusa.com) software
package. Four randomly selected cells per high power field were
outlined, and cell size was calculated on the basis of microns per
pixel.
GFP Labeling
Reporter constructs for the MLC2v and MLC2a promoters in the
pAcGFP1-1 vector were used to generate recombinant adenovi-
ruses as detailed elsewhere [16]. Viral infections of iPSC-CMs
were performed at a multiplicity of infection of 100. Plates were
placed into the IncuCyte incubator (Essen Bioscience, Ann Arbor,
MI, http://www.essenbioscience.com) and monitored for cell
growth for 60 hours.
Calcium Transients and Optical Mapping Studies
iPSC-CM monolayers in 12-well plates were loaded with Rhod-2,
AM (5 mmol/l, Molecular Probes, Thermo Fisher) for 10 minutes
to monitor intracellular calcium flux and wave propagation using
a previously described LED illumination optical mapping system
[17, 18]. A bipolar electrode attached to an electrical stimula-
tor (Myopacer Field Simulator, 10N, IonOptix, Westwood, MA,
http://www.ionoptix.com) was used to electrically pace mono-
layers at 0.5 Hz. In separate experiments, responsiveness to
isoproterenol (50 nmol/l) was evaluated 45 days after cardiac in-
duction in 96-well plates. Briefly, monolayers were loaded with
Rhod-2 (100 ml/well, Molecular Probes) in dimethyl sulfoxide at
37°C for 20minutes. Spontaneous beating rate, calcium transient
amplitude, and durationwere quantified before and after isopro-
terenol treatment.
Statistical Analysis
Quantitative data analyses were performed in triplicate and pre-
sented as the mean 6 SD. The data were analyzed by Student’s
t test or analysis of variance with Bonferroni correction for mul-
tiple comparisons using GraphPad Prism software (version 6.0e,
GraphPad, La Jolla, CA, http://www.graphpad.com). Resultswere
considered to be statistically significant if p # .05, unless other-
wise stated.
RESULTS
Human AF-MSCs Have Restricted
Differentiation Potential
We isolated human AF-MSCs in the absence of cell sorting and
confirmed their phenotype after several weeks in culture. In com-
parisonwith spindle-shapedneonatal dermal fibroblasts grown in
Jiang, Herron, Di Bernardo et al. 1597
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Figure 1. Characterization of human amniotic fluid mesenchymal stromal cells (AF-MSCs) before and after cellular reprogramming with non-
integrating Sendai virus (SeV, passage 4, magnification,310). Human skin dermal fibroblasts were reprogrammed in parallel experiments as
controls. (A):Representative phasecontrastphotomicrographs illustrating the typicalmorphologyof skinandamniotic fluid cells (upperpanels).
Immunofluorescence microscopy of cells merged with 49,6-diamidino-2-phenylindole (in blue) showing lack of expression of the pluripotency
marker, NANOG, in both cell types (lower panels). (B): Immunofluorescencemicroscopy of representativemesenchymal skin and amniotic fluid
cells under adipogenic conditions showing expression of adipogenic marker, fatty acid binding protein 4 (upper panels, magnification, 340).
Immunofluorescence microscopy of representative mesenchymal skin and amniotic fluid cells under osteogenic conditions demonstrating ex-
pression of osteogenic marker, osteocalcin (lower panels, magnification, 340). (C): Flow cytometric characterization of representative skin
dermal fibroblasts and AF-MSCs (positive shown in red in comparison with blue negative control) grown inmesenchymal basal media, confirm-
ing a mesenchymal stromal immunophenotypic profile. (D): Representative colony morphology, alkaline phosphatase staining (inset), and im-
munofluorescence profile of skin- and amniotic fluid (AF)-induced pluripotent stem cells (iPSCs) showing similarities with human embryonic
stem cell (ESC) controls (magnification, 320). (E): Immunofluorescence microscopy of representative adherent embryoid bodies from skin-
iPSCs, AF-iPSCs, and ESCs showing spontaneous three-germ layer expression of b-III tubulin (ectoderm), SOX17 (endoderm), and a-smooth
muscle actin (mesoderm), magnification, 320. (F): Representative reverse transcription polymerase chain reaction from skin- and AF-iPSC
clones demonstrating maintenance of NANOG but loss of SeV transgene sequences at later passages. Double distilled water was a negative
control. (G): Representative karyotype analysis of skin- and AF-iPSC colonies based on 20 G-banded metaphase cells, indicating normal chro-
mosomes (passage 17). Abbreviations: AF-MSC, amniotic fluid mesenchymal stromal cells; AP, alkaline phosphatase; DAPI, 49,6-diamidino-2-
phenylindole; DDW, double distilled water; EB, embryoid bodies; ESC, embryonic stem cell; FABP4, fatty acid binding protein 4; iPSC, amniotic
fluid-induced pluripotent stem cells; OCN, osteocalcin; SeV, Sendai virus; a-SMA, alpha-smooth muscle actin.
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parallel, the majority of amniocytes had a more distinct, oval-
shaped morphology after the first passage (Fig. 1A). As was
expected, immunofluorescent staining showed lack of expres-
sion of the pluripotency marker, NANOG, in both cell types
(Fig. 1A). AF-MSCs were successfully maintained in continuous
culture for 4 weeks (3.7 3 107 cells at passage 4) without
morphologic change or reduced cell proliferation.
To characterize the baseline differentiation potential of
unsorted AF-MSCs, we performed directed differentiation to-
ward the mesodermal lineage. We confirmed that a subset of
AF-MSCs were capable of differentiating into two mesodermal
cell types, adipocytes and osteoblasts, when cultured in the ap-
propriate directive media for 3 weeks. Evidence of adipogenic
differentiation was indicated by the presence of Oil Red
O-positive lipid vacuoles within the cytoplasm of a subpopula-
tion of AF-MSCs (data not shown) and by expression of fatty acid
binding protein 4 (Fig. 1B) by immunofluorescence. There was
osteogenic differentiation, as evidenced by increased extracel-
lular calciummatrix staining in the presence of Alizarin Red (data
not shown) and by positive expression of the late osteogenic
marker, OCN (Fig. 1B).
The immunophenotypic profile of AF-MSCs was further char-
acterized by flow cytometry. Both AF-MSCs and dermal fibro-
blasts uniformly expressed surface epitope markers typically
associatedwithbonemarrow-derivedmesenchymal stromal cells
(Fig. 1C). For AF-MSCs and dermal fibroblasts, expression of CD44
was 98.9%6 1.4% and 97.3% 6 2.5%, CD73 was 91.9% 6 4.5%
and 99.5% 6 0.4%, CD90 was 94.9% 6 5.3% and 95.9% 6
3.1%, and CD105 was 95.6% 6 3.5% and 98.3 6 2.1%, respec-
tively. In contrast, less than 1% of all samples expressed HLA-
DR or stem cell markers, including CD34, CD45, NANOG, and
OCT4A. The expression of CD117 among AF-MSCs was uniformly
low (0.9% 6 0.1%; data not shown).
Reliable Reprogramming of Amniocytes Using
SeV Vectors
To epigenetically reprogram AF-MSCs into transgene-free iPSCs,
we used nonintegrating SeV allowing for controlled overexpres-
sionofOSKM.Under standard ESC conditions, AF-MSCsuniformly
began to aggregatewhile reducing cytoplasmic volumeand losing
their spindle-shaped morphology between 14 and 21 days in cul-
ture (Fig. 1D). After 28 days, there were multiple candidate iPSC
colonies with well-defined borders and high nuclear-to-cytoplasm
ratios analogous toundifferentiated ESCs.We confirmed thatmor-
phologically distinct AF-iPSCs expressed high levels of alkaline
phosphatase (Fig. 1D, inset). The overall reprogramming efficiency
of AF-MSCs into iPSCs using SeV encoding for OSKM ranged from
0.01% to 0.05%.
Between four and sixweeks after exposure to SeV reprogram-
ming factors, individual AF-iPSC clones were mechanically picked
and successfully transferred onto Matrigel-coated dishes for fur-
ther expansion, subculture, and additional characterization. Im-
munofluorescence staining revealed uniformly high expression
of NANOG, OCT4, SOX2, SSEA3, SSEA4, TRA-1-60, and TRA-1-81
within AF-iPSC colonies in a pattern similar to that seen with der-
mal skin-iPSCs and ESC colonies (Fig. 1D).
To confirm that AF-iPSCs were capable of trilineage differen-
tiation in vitro, we allowed clones to spontaneously differentiate
in low-adherence cultures as EBs. Whereas AF-MSCs had nei-
ther the ability to form EBs nor the capability of surviving in
suspension, AF-iPSCs exhibited robust EB formation. Immunocy-
tochemical analysis of AF-iPSC-EBs confirmed the presence of
derivatives of three germ layers similar to EBs generated from
skin-iPSCs and ESCs. AF-iPSC-EBs expressed the endoderm
markers, SOX17 (Fig. 1E) and FOXA2 (data not shown). Mesoder-
mal differentiation was confirmed by the presence of a-SMA
(Fig. 1E), and ectodermal differentiation was exhibited by
positive b-III tubulin (Fig. 1E) and Nestin (data not shown)
expression.
Evidence of residual genomic integration of SeV vectors in
iPSCswas evaluated by RT-PCR. As expected, therewas strong ex-
pression of the pluripotency marker, NANOG, among all AF-iPSC
and skin-iPSC clones at later passages. In contrast, levels of the
SeV transgene were nearly undetectable beyond passage 10
(Fig. 1F). Cytogenetic analyses showed normal karyotypes, indi-
cating that AF-iPSCs remained free of nonclonal aberrations after
continuous in vitro expansion for up to passage 20 (Fig. 1G).
Transgene-Free Amniocytes Could Be Reliably Induced
Toward the Cardiac Lineage
We subjected six different AF-iPSC clones to cardiogenic condi-
tions by using either the Matrigel sandwich (n = 3 experiments)
or small-molecule (n = 1 experiment) protocol. Schematic dia-
grams of CM differentiation are shown in Figure 2A and 2B, re-
spectively. Between 7 and 10 days after induction, amniotic
fluid-derived cells began to spontaneously contract, consistent
with CM differentiation. Cardiac induction was reliably achieved
with similar efficiency from all clones using either differentiation
protocol. Over time, the majority of cells continued to beat in a
coordinated, rhythmic fashion (mean frequency, 100.8 6 16.2
beats per minute at 37.5 days; supplemental online video), and
spontaneously contracting cells could be maintained in culture
for at least 90 days. Immunofluorescence staining approximately
4 weeks after induction showed strong expression within con-
tracting cells of MYH7, a-actinin, and MF20, in a pattern similar
to that observed with skin-CMs and ESC-CMs, which confirmed
directed differentiation of transgene-free AF-iPSCs into func-
tional CMs (Fig. 2C). Over time, there was alignment and in-
creased density of myofilaments within individual AF-CMs, as
displayed by robust immunofluorescence staining for a-actinin
andcTnT (Fig. 2D).WecouldmaintainAF-CMsunder these cardio-
genic conditions for at least 90 days.
Qualitative gene expression analyses of transgene-free
AF-CMs performed between 30 and 60 days after cardiac induction
showed upregulation of multiple CM-specific genes (Fig. 2E),
namely MYH6, MYH7, TNNT2, MLC2a (MYL7), MLC2v (MYL2),
and TTN, in AF- and skin-CMs, in comparison with controls when
normalized in relation to the housekeeping gene, GAPDH. Gene
expression ofMYH7, TNNT2, MLC2a, MLC2v, and TTNwas signif-
icantly increased in AF-CMs in comparisonwith skin-CM controls.
As was expected, pluripotency genes, including NANOG, OCT4,
SOX2, and TERT, were uniformly downregulated in AF- and skin-
CMs after induction in comparison with parental controls (Fig. 2E).
Taken together, these results are consistent with differentiation of
stem cells to functional CMs.
AF-CMs Are Composed of Multiple Cardiac Subtypes
To obtain a more homogeneous population of transgene-free
CMs for subsequent phenotypic characterization and functional
testing, both AF-CMs and skin-CMs were enriched on the basis
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of SIRPA+ expression between 30 and 40 days after induction. In
comparison with unsorted cells whose SIRPA expression was be-
tween 53.2% and 65.3%, greater than 90% enrichment for SIRPA
was obtained in all samples after magnetic bead separation (Fig.
3A). CM purity for AF-CMs and skin-CMs, as determined by flow
cytometry based on cTnT expression, was 96.8% 6 0.83% and
93.2% 6 2.68%, respectively. There were no significant differ-
ences in cTnT expression between AF-CMs and skin-CMs after
sorting (p= .057). Todetermine thedegreeof hypertrophy among
sorted cells, we measured relative cell size and found it to be,
on average, 68% greater in AF-CMs than in skin-CMs (p = .029,
Fig. 3B). Confocal microscopy of AF- and skin-CMs showed multi-
ple CM subtypes on the basis of immunostaining for various sarco-
meric proteins, including MLC2v, MYH7, MF20, MLC2a, and
TNNT2 (Fig. 3C).
To accurately determine the relative frequency of atrial- and
ventricular-like CMs derived from SIRPA+ AF-CMs, we measured
MLC2a and MLC2v promoter activity driving green fluorescent
protein (GFP) expression for more than 24 hours. As is shown
byGFPcell imaging (Fig. 3D), therewasproliferationand relatively
stable MLC2a- and MLC2v-GFP expression among AF-CMs in a
similar profile when compared with skin-CMs. There were no
Figure 2. Directed differentiation of representative transgene-free amniotic fluid-induced pluripotent stem cells (iPSC) clones from am-
niotic fluid into cardiomyocytes (CMs) in vitro. (A): Schematic of Matrigel sandwich CM induction (n = 3 separate experiments). (B): Sche-
matic of small-molecule CM induction (n = 1 experiment). (C): Skin- and amniotic fluid-derived cardiomyocytes (AF-CMs) at day 38 of
induction revealing positive immunofluorescent staining for myocyte markers (Cy3 secondary, red), including MYH7, a-actinin, and
MF20 (magnification, 340), merged with DAPI, compared with embryonic stem cell (ESC) controls. (D): Immunofluorescence staining
of AF-CMs at day 90 using antibodies against a-actinin and cardiac troponin (Cy3 secondary, red) showing densely aligned and well-
organized myofilament structures superimposed with DAPI (magnification,340). (E): Quantitative analysis by quantitative polymerase
chain reaction , demonstrating marked upregulation of cardiac-specific genes—including MYH6, MYL7 (MLC2a), TNNT2, MYH7, MYL2
(MLC2v), and TTN—in skin- and AF-CMs after 42 days of induction in comparison with skin fibroblast (FB) and amniotic fluid controls.
Gene expression of MYH7, TNNT2, MYL7, MYL2, and TTN was significantly increased in AF-CMs in comparison with skin-CM controls.
Pluripotency genes—such as NANOG, OCT4, and TERT—were downregulated. Data were normalized in relation to housekeeping gene
(GAPDH) and presented as the mean 6 SEM. p, p # .05 in comparison with skin-CMs; n = 3 independent biological replicates.
Abbreviations: AF-CMs, amniotic fluid-derived cardiomyocytes; BMP4, bone morphogenetic protein 4; CMs, cardiomyocytes; DAPI,
49,6-diamidino-2-phenylindole; ESC, embryonic stem cell; FB, fibroblast; iPSC, amniotic fluid-induced pluripotent stem cells; MSC,
mesenchymal stem cell.
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significant differences between atrial- and ventricular-like speci-
ficationofAF-CMsat 24hours (52.7%and47.3%, respectively). To
further characterize the presence of nodal-like subtypes within
AF-CMs,wemeasured thegeneexpressionofHCN4, an important
membrane channel specific for the sinoatrial node (Fig. 3E).HCN4
expression was strongly upregulated after cardiac differentiation
in AF-CMs, similar to skin-CMs, when compared with control pa-
rental cells. There was also marked upregulation in the KCNJ2, a
gene encoding for an inwardly rectifying potassium channel, in
AF-CMs, similar to expression observed in skin-CM controls. Fi-
nally, confocal microscopy of AF-CMs showed expression of the
critical gap junction protein, connexin-43 (GJA1), in conjunction
with the microfilament protein, a-actinin.
Global Gene Expression of AF-CMs Is Similar to That
of Skin-CMs
To determine any similarities and differences between AF-CMs
and skin-CMs, we tested iPSC clones with parental somatic cells
and SIRPA+ CMs (induction day 31) in targeted microarray analy-
ses. A representative dendrogram of one-way unsupervised hier-
archicial clustering analysis of global expression profiles showed
that AF-iPSCs clustered closely with skin-iPSCs (Fig. 4A). Both
iPSCs were distinct from parental AF-MSCs and clustered re-
motely with dermal fibroblasts (Fig. 4A). Although global gene
expression patterns of AF-iPSCs were divergent from those of
AF-MSCs (R2 = .58) and AF-CMs (R2 = .28), AF-CMs arrays were
Figure 3. Characteristics of transgene-free amniotic fluid-derived cardiomyocytes (AF-CMs) at induction day 38, n = 3 independent biological
replicates. (A): Vertical bar graph showing high enrichment for cardiac troponin cells in both skin-CMs (93.2% 6 1.3%, black) and AF-CMs
(96.8% 6 0.4%, white) after positive selection based on signal regulatory protein (SIRPA) expression. Data are presented as mean 6 SD,
n = 3 independent biological replicates. (B): Vertical bar graph demonstrating a significant increase in the relative size of AF-CMs in comparison
with skin-CMs (3.16 0.3, black) and AF-CMs (5.26 0.3, white). Data are presented as mean6 SD. p, p # .05 in comparison with control, n = 3
independent biological replicates. (C):Confocalmicroscopyof skin- andAF-CMsubtypes exhibiting comparablemixed immunostaining patterns
of sarcromeric proteins, including ventricular CMs (myosin light chain 2v [MLC2v], fluorescein isothiocyanate [FITC] secondary, green) in
conjunction with other cardiac-specific markers, includingMYH7, MF20, MLC2a, and TTNT2. Nuclei were counterstained in DAPI in all images.
(D): Quantification of SIRPA+ CM subtypes at 0 hours (left) and 24 hours (right) in culture showing relatively stable MLC2a- and MLC2v-green
fluorescentprotein (GFP)expressionamongskin-CMs (black) andAF-CMs (white).Dataarepresentedasmean6SD,n=4 independentbiological
replicates. (E):Quantitative gene expression analysis by quantitative polymerase chain reaction demonstrating upregulation of cardiac-specific
membrane channel genes, includingHCN4 (sinoatrial node, top) andKCNJ2 (inwardly rectifyingpotassiumchannel, bottom), in skin- andAF-CMs
in comparisonwith control parental cells. Datawerenormalized in relation to thehousekeeping gene (GAPDH) andpresented as themean6 SD.
p, p # .05 in comparison with control, n = 3 independent biological replicates. (F): Confocal microscopy of skin- and AF-CMs demonstrating
expression of the gap junction protein, connexin-43 (CX43, FITC secondary, green), in conjunctionwith themicrofilament protein,a-actinin (Cy3
secondary, red). Nuclei were counterstained with DAPI. Abbreviations: AF-CMs, amniotic fluid-derived cardiomyocytes; cTnT, cardiac troponin
cells; DAPI, 49,6-diamidino-2-phenylindole; FB, fibroblast; MLC2, myosin light chain 2; MSC, mesenchymal stem cell; SIRPA, signal regulatory
protein.
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closely aligned with patterns observed in skin-CMs (R2 = .85; Fig.
4B). To assess the similarities and differences between CMs in
more detail, a heatmap focusing on upregulated and down-
regulated genes was generated, which revealed transcriptome
patterns in AF-CMs that were nearly identical to those found in
skin-CMs (Fig. 4C). In accordance with the qPCR data, focused
analysis of key sarcomere structural genes—including ACTC1,
MYH6, and NEBL—showed upregulation in both AF-CMs and
skin-CMs with no significant differences between the groups.
AF-CMs Demonstrate Robust Functional Activity
The spontaneous beat rate of representative CMs from iPSCs was
measured by counting spontaneous calcium transients. There
were no significant differences in the beat rate per minute be-
tween skin- and AF-CMs when measured early after induction
on day 21 (12.3 6 5.5 vs. 21.5 6 9.9) or day 28 (38.9 6 14.2
vs. 26.06 10.9, respectively; Fig. 5A).
Between days 38 and 45 after induction, SIRPA+ AF-CMs un-
derwent functional testing in parallel with SIRPA+ skin-CMs as
controls. AF-CMs had a significantly faster mean spontaneous
beat rate of 73.8 6 5.4 beats per minute (frequency of 1.23 6
0.09, n = 15) in comparisonwith skin-CMs (mean 48.66 3.6 beats
perminute, 0.816 0.06Hz, n = 9). To further investigate the func-
tional properties of AF-CMs,wemeasured calciumhandling prop-
erties by using fluorescent imaging techniques. Line scan plots
and single pixel recordings made during 5-second intervals
showed that AF-CMs exhibited a spontaneous rhythmic fre-
quency and timing comparable to those of control skin-CMs
(Fig. 5B, 5C, respectively). We then conducted optical mapping
studies to measure the wave propagation characteristics of AF-
CMs and found isotropic propagation patterns of intracellular
Figure 4. Representative microarray analysis of transgene-free signal regulatory protein amniotic fluid-derived cardiomyocytes (AF-CMs) (in-
duction day 31) in comparison with controls, n = 2 independent biological replicates. (A): Dendrogram showing the unsupervised hierarchal
clustering of the global expression profiles for amniotic fluid-induced pluripotent stem cells (AF-iPSCs), parental AF-mesenchymal stem cell
(MSC), skin-iPSCs, and dermal fibroblasts. (B):Global gene expression profiles of AF-CMs shown in scatter plots revealing close correlation with
patterns observed in skin-CMs (R2 = .85, bottom right) in comparison with parental AF-iPSCs (R2 = .28, top right). R2 denotes the coefficient of
determination. (C): Heatmap image illustrating the relationship of 88 genes, grouped on the basis of hierarchical clustering, which were dif-
ferentially upregulated or downregulated in AF-CMs, skin-CMs, AF-MSCs, and dermal fibroblasts. The transcriptome patterns expressed by
AF-CMs were similar to those expressed by skin-CMs. Higher and lower levels of transcripts are shown in red and yellow, respectively. Listings
of genes in group 1 and group 2 are presented in supplemental online Tables 3 and 4, respectively. GEO link: http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc = GSE76965. Abbreviations: AF-MSC, amniotic fluid mesenchymal stem cell; CMs, cardiomyocytes; iPSC, amniotic fluid-
induced pluripotent stem cells.
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calcium transients in AF-CM monolayers that were similar to
those observed in skin-CMs (Fig. 5D). To further analyze calcium
handling properties in response to b-adrenergic receptor stim-
ulation, we exposed AF-CMs to isoproterenol (50 nM). AF-CMs
demonstrated appropriate chronotropic responses, as shown
by a statistically significant increase in the beat frequency in
comparison with baseline and stimulated skin-CMs (p = .008;
Fig. 5E, 5F). Taken together, AF-CMs electrically matured in mono-
layer cultures in similar fashion to those observed with skin-CMs.
DISCUSSION
Our laboratory has previously shown that transgene-free iPSCs
can be generated from somatic cells derived from amniotic fluid
samples from normal and abnormal pregnancies [10]. Although
the generation of iPSCs from amniotic fluid has been well docu-
mented by multiple groups [19–22], there remains little to no
data on their systematic differentiation potential toward the
CM lineage [23]. In this study, we show that human amniotic fluid
cells with restricted differentiation potential can be reprogrammed
using nonintegrating SeV and subsequently used to generate func-
tional CMs with robust and highly organized myofilament struc-
tures. We also demonstrate that a diverse population of relatively
mature CMswas produced, expressingMLC2v,MLC2a, and TNNT2,
among others transcripts. The majority of these cells expressed
SIRPA, which is present on human fetal CMs as well as on iPSC-
derivedCMs fromtheearliest cardiac stage [14].Given thatourdata
showed that SIRPA+AF-CMs respondedappropriately topharmaco-
logic stimulation, these studies suggest that we may have an
in vitro platform for the testing of other agents, including
Figure 5. Functional characterization of transgene-free amniotic fluid-derived cardiomyocytes (AF-CMs). (A): Spontaneous beat rate per min-
ute of representative CMs derived from skin and amniotic fluid at day 21 and day 28 after cardiac induction. p, p # .05. (B): Representative line
scan images of signal regulatory protein (SIRPA+) CMs derived from skin (left) and amniotic fluid (right) during a 5-second interval. (C): Repre-
sentative single-pixel recordings of SIRPA+ skin- and AF-CMs during a 5-second interval. (D): Representative pseudocolor activation map of in-
tracellular calcium transient propagation in SIRPA+ skin-CM (top) and AF-CM (bottom) monolayers showing similar circular spreading patterns
after spontaneous activation. Isochrone lines indicate differential activation times. (E): Representative calcium transient recordings after
b-adrenergic agonist (50 nM isoproterenol [ISO]) exposure of SIRPA+ skin- and AF-CMs demonstrating appropriate chronotropic responses
in comparison with baseline. (F):Measurement of baseline frequencies revealing faster spontaneous beat rate among representative SIRPA+
AF-CMs (n=15) in comparisonwith skin-CMs (n=9). Recordings after 50nMISOexposureof skin- andAF-CMs,demonstrating an increase inbeat
frequencies. p, p # .05 in comparison with control. Abbreviations: AF-CMs, amniotic fluid-derived cardiomyocytes; d21, day 21; ISO, isoproterenol.
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morphogens andgrowth factors,whichhave the potential to en-
hance early CM function, differentiation, or both.
The entire process from a 10-ml amniotic fluid sampling
to transgene-free CM generation took fewer than 16 weeks
(i.e., 2–3weeks forAF-MSCculture, 6–8weeks for iPSC colony for-
mation and expansion, and approximately 3–4 weeks for CM dif-
ferentiation), using a highly reproducible protocol in all six iPSC
clones tested. In most cases of prenatally diagnosed CHD,
AF-CMs could be available for personalized application, including
in vitro testing and autologous transplant-based therapies, at
the time of their initial palliative heart surgical reconstruction
as neonates. Use of more defined cardiac differentiation proto-
cols, including those using small molecules as shown in our
study, strengthens the notion that the generation of AF-CMs
is not protocol specific. Our findings are consistent with the
work of others showing that CMs derived from dermal fibro-
blasts using small molecules have indistinguishable cardiac phe-
notypic and calcium-handling properties when compared with
those generated using the Matrigel sandwich technique [24].
The small-molecule approach may further reduce concerns re-
garding the safety of these cells when delivered for therapeutic
purposes [25].More rapid generation of AF-CMsbydirect differ-
entiation of somatic cells may also be possible in the near future
on the basis of reports documented elsewhere [26, 27].
Our highly enriched AF-CMs were essentially indistinguish-
able from those derived from dermal fibroblasts.While postnatal
dermal fibroblasts will likely remain the somatic cell of choice for
basic cardiac research aimed at mechanistically dissecting the
processes involved in cardiac differentiation from iPSCs, the gen-
eration of CMs for therapeutic purposes in prenatally diagnosed
CHD favors the use of autologous amniocytes as the parental cell
of choice [28].Moreover, amniocytes offer numerous advantages
over postnatal cells, because the former proliferatemore rapidly,
may be easier to reprogram toward pluripotency, are more re-
sponsive to directed differentiation, and harbor few to no spon-
taneous genetic aberrations [21, 29, 30].
Because most major fetal cardiac anomalies are initially diag-
nosedbetween20weeks and24weeks gestation [31], generating
CMs from amniotic fluid would be the least invasive strategy for
facilitating both early in vitro testing and effective stem cell ther-
apy in either the prenatal or postnatal period. At 24 weeks
gestation, from a volume of amniotic fluid of approximately 600 ml
surrounding the fetus [32], a 10-ml aliquot obtained by amniocen-
tesisavoids the inherent riskofhemorrhage,pretermlabor,andfetal
demise associatedwith a fetal skin or placenta biopsy [7]. An amnio-
centesis also has virtually no added morbidity because it is often a
recommendedtest conducted in theprenatalworkupofamajor car-
diac anomaly to rule out an abnormal karyotype [33]. Furthermore,
our group, among others [34], has previously shown that amniotic
fluid cells can be harvested without maternal cell contamination
and are therefore derived exclusively from the fetus [10]. The tra-
ditional paradigm of creating autologous cardiac tissues from
postnatal tissue may lead to undesirable delays in therapy
and potentially poorer outcomes in those with severe CHD [28].
The differentiation of human embryonic and other fetal stem
cell derivatives intoCMshasalsobeenproposed forpotential clin-
ical translation in pediatric cardiac disease [35]. Options would
include “off-the-shelf” stem cell products, such as CD117+ amni-
otic fluid stem cells (AFSCs), dermal fibroblast-derived iPSCs,
and ESCs [36–38]. Although these alternative cells types are
attractive for many reasons and would offer some potential
advantages clinically, they are hampered by other issues, in-
cluding possible immunologic rejection due to major and minor
major histocompatibility differences [38]. Moreover, concerns re-
garding inadvertent tumor formation with ESCs and many iPSCs
when injected in vivo have limited enthusiasm for their clinical
translation potential [39]. Finally, ethical objections to the use of
human ESC-based therapies in the United States and elsewhere
on the basis of religious/social norms should not be underesti-
mated [40].
Most critical CHD—including tetralogy of Fallot, transposition
of thegreat vessels, andhypoplastic left heart syndrome (HLHS)—
are complex structural problems resulting from poorly under-
stood global errors in cardiac morphogenesis. Unlike hypertrophic
cardiomyopathy and congenital arrhythmias, both of which have
been shown to recapitulate the disease phenotype in iPSCmodels
[41, 42], CM function inmost critical CHD patients is believed to be
intrinsically normal in the majority of cases, suggesting that most
cases of CHD-associated heart failure may be amenable to autolo-
gous cell therapy.Additionally, becauseamniotic fluid andAF-iPSCs
cells can be easily banked, our approach is highly scalable and not
limited by cell scarcity for most perinatal applications, including
the study of 3D microtissue formation, as well as the delivery of
AF-CMs to rescue heart failure or augment existing function dur-
ing the initial palliative operation [35, 43–45]. Assuming that
adequate proliferation of AF-iPSCs can be established and main-
tained in culture, this technology could also be used to seed an
entire decellularized heart with CMs in time for implantation
during early infancy [46]. From a 10-ml aliquot of amniotic fluid,
at least 1.353 107 cTnT+ cells could be easily generated before
birth by using our highly scalable approach. On the basis of clin-
ical translation studies performed by others [47–49], approxi-
mately 2–4 3 107 CMs would be required to extensively
remuscularize the damaged heart of a 3-kg neonate with con-
genital heart disease.
Unlike endogenous resident CM progenitors isolated from
heart biopsies [50, 51], the study of amniotic fluid-based iPSCs
would additionally allow investigators to identify genes and mo-
lecular regulatory networks thatmediate early CMdifferentiation
andmorphogenesis in anyprenatally diagnosedpatient. ForHLHS
and other forms of critical CHD, this in vitro platform would be
ideally suited to study patient-specific developmental defects
that may lead to differences in myocardial patterning [52]. Al-
though somaticmutations inNKx2-5,NOTCH1,GATA4, andHAND1
have been implicated in the pathogenesis of CHD [53, 54], other
investigators have not been able to substantiate these findings
[6, 55]. Because the cause is largely unknown in the vast majority
of critical CHD, it is likely that no single gene defect is specifically
linked in most cases of CHD.
Novel insights into disease pathogenesis may also be gained
using this AF-iPSC-based cardiac differentiation protocol in terms
of understanding the role of resident, SIRPA2 non-CMs, which
likely include vascular smoothmuscle cells, fibroblasts, and endo-
thelial cells that are vital in supporting normal CM development
within 3D microtissues [56]. Moreover, the study of AF-CMs
from critical CHD amniotic fluid within bioreactors could be
used to explore how aberrant physiologic conditions in utero
(e.g., hypoxia, laminar flow, stretch, compression) affect CM
differentiation [51].
In our study, the isolated cells from amniotic fluid had a phe-
notype that was consistent with that of MSCs [8, 57]. Because
these AF-MSCs had an intermediate phenotype between that
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of true pluripotent stem cells and fully differentiated adult stro-
mal cells [58–60], our amniocytes should not be confused with
CD117+ AFSCs [37]. AlthoughbothAF-MSCs andAFSCs proliferate
easily in culture, our group, amongothers, has shown thatAF-MSCs
undergo senescence following repetitive passaging, are not plurip-
otent, and cannot be differentiated directly into CMs using estab-
lished protocols [60]. In contrast, AFSCs have beenelegantly shown
to be pluripotent on the basis of a transgene-free, chemical-based
approach using the histone deacetylase inhibitor, valproic acid
[61]. However, because a rare (,1%) clonal population of
CD117+ amniotic fluid cells must be isolated and cultured for
months, their use for autologous purposes at birth may not
be feasible [62]. It is also not entirely clear as to whether
CD117+ cells are reliably present in every amniotic fluid specimen
[63], particularly during the time period when critical CHD is typ-
ically diagnosed by fetal echocardiography (i.e., between 20 and
24 weeks gestation) [64].
Despite the promising data generated from this study, there
are some limitations. iPSC reprogramming of any somatic cell us-
ing SeV is still a technically demanding endeavor, and multiple
passages were required before loss of the SeV transgene was ev-
ident. Although AF-CMs displayed similar behavior as did skin-
CMs, comparisons with additional control CMs that were directly
derived from human fetal/neonatal cardiac tissue would be ideal
tobetterunderstand their relativebehavior andefficacy in clinical
applications. Our CM differentiation protocols will also require
furthermodifications prior to preclinical and clinical use, because
they are neither completely chemically defined nor free from
animal products. Recently, other investigators have made signif-
icant progress in establishing fully chemically defined differenti-
ation and xenogeneic-free protocols for the generation of CMs
[25]. There may also be variations in the differentiation capabil-
ities of various iPSC clones, which is beyond the scope of our
study. Finally, evaluation of additional patient samples, particu-
larly from fetuseswith prenatally diagnosed CHD,would behighly
desirable because, to our knowledge, iPSC-based technologies
have not been described in nonsyndromic cases of major struc-
tural CHD. Experiments in the laboratory are currently focusing
on transgene-free AF-CMs generated from patients with HLHS
and other various forms of critical CHD.
CONCLUSION
The present study demonstrates that cells from second-trimester
human amniotic fluid can be reliably reprogrammed and induced
into mature, functional CMs free of reprogramming factors. Be-
cause most critical CHD can be detected in utero, this approach
has the potential to generate patient-specific, therapeutic-grade
CMs amenable for autologous cell transplantation before a child
is even born.
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